Evidence map›Paper›PMID 38367037›Full record

GuidelineArchives of women's mental health2024

French Society for Biological Psychiatry and Neuropsychopharmacology and French-speaking Marcé Society guidelines for the management of mood disorders in women before, during, and after pregnancy.

Raoul Belzeaux, Florence Gressier, Ludivine Boudieu, Adeline Arnould, Elsa Moreau, Julia Pastol, Eleni Tzavara, Anne Laure Sutter-Dallay, Ludovic Samalin

Abstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Archives of women's mental health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Guideline
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Raoul BelzeauxFrench Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France. raoul.belzeaux@chu-montpellier.fr.
Florence GressierSociété Marcé Francophone, Chatenay Malabry, France.
Ludivine BoudieuDepartment of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, (UMR 6602), Clermont-Ferrand, France.
Adeline ArnouldFrench Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.
Elsa MoreauFrench Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.
Julia PastolFrench Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.
Eleni TzavaraPôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France.
Anne Laure Sutter-DallaySociété Marcé Francophone, Chatenay Malabry, France.
Ludovic SamalinFrench Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.
Centre National de la Recherche Scientifique · FRAssistance Publique Hôpitaux de Marseille · FRInserm · FRUniversité Paris-Saclay · FRUniversity of Clermont Auvergne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe French Society for Biological Psychiatry and Neuropsychopharmacology and the French-speaking Marcé Society have joined forces to establish expert recommendations on the prescription of psychotropic drugs before, during, and after pregnancy in women with major depressive disorder (MDD) and bipolar disorder (BD).

methodsTo elaborate recommendations, we used the RAND/UCLA Appropriateness Method, which combines scientific evidence and expert clinicians' opinions. A written survey was completed by 48 psychiatrists, who have expertise in the management of mood disorders and/or in perinatal psychiatry. Key recommendations are provided by the scientific committee based on data analysis and interpretation of the results of the survey.

resultsThe recommendations address the following three areas that are deemed essential in women with mood disorders, with an emphasis on screening, treatment options, and monitoring: (i) management of mood disorders in women of childbearing age, (ii) management during pregnancy, (iii) management during the post-partum period. As first-line strategies, experts recommend treating mood symptoms during pregnancy and maintaining a pharmacological treatment, even in euthymic or stabilized patients. First-line options include only medications with no teratogenic risk, and during breastfeeding, only medications without evidence of adverse effects in nursing infants.

conclusionThe expert consensus guidelines will help facilitate treatment decisions for clinicians in the daily assessment and management of mood disorders in women of childbearing age, during pregnancy, and in the post-partum period.

Indexed as

Mood DisordersPregnancy ComplicationsAdultBiological PsychiatryBipolar DisorderFemaleFranceHumansMajor Depressive DisorderPregnancyPsychopharmacologyPsychotropic DrugsSocieties, MedicalPsychotropic DrugsBipolar disorderChildbearing ageMajor depressive disorderMood disordersPost-partum pharmacotherapyPregnancy

Identifiers

PMID38367037
OpenAlexW4391913771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.